| Rank |
Status |
Study |
| 1 |
Recruiting
|
Stress Biomarkers Among Patients Undergoing Treatment for Excited Delirium and Severe Pain in the Emergency Department
| Conditions: |
Agitation; Excited Delirium; Pain |
| Intervention: |
|
| Outcome Measures: |
Change in Altered Mental Status Score; Change in Visual Analog Scale Pain Score; Change in Serum Total Catecholamines; Length of Hospital Stay; Mortality; Complications; Change in Heart Rate; Change in Systolic Blood Pressure; Change in Mean Arterial Pressure; Disposition; Change in Body Temperature; Change in end tidal carbon dioxide; Change in Oxygen Saturation |
|
| 2 |
Not yet recruiting
|
Effect of Deksmedetomidine and Remifentanil in Extubation Agitation
| Condition: |
Agitation |
| Interventions: |
Drug: deksmedetomidine; Drug: Remifentanil; Drug: Saline |
| Outcome Measures: |
To asses postoperative Agitation score by Riker sedation Agitation scale; Yo asses postoperative side effects emesis, vomitting or pain |
|
| 3 |
Not yet recruiting
|
Ketamine Versus Haloperidol for Severe Agitation Outside the Hospital
| Condition: |
Agitation |
| Interventions: |
Drug: Ketamine; Drug: Haloperidol |
| Outcome Measures: |
Time from injection of drug to adequate sedation, defined as a score of 0 or less on the AMSS.; Number of participants intubated.; venous pH; serum potassium; Total time the participant is a patient in the Emergency Department.; Number of patients admitted versus number of patients discharged.; venous lactate; Number of patients experiencing laryngospasm.; Number of patients experiencing dystonia. |
|
| 4 |
Recruiting
|
Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
| Conditions: |
Agitation Associated With; Alzheimer's Disease; Alzheimer's Type; Mental Disorder; Nervous System Diseases |
| Intervention: |
Drug: Brexpiprazole, OPC-34712 |
| Outcome Measures: |
Change in the Cohen-Mansfield Agitation Inventory (CMAI) total score; Change in the Clinical Global Impression Severity of Illness (CGI-S) score, as related to symptoms of Agitation |
|
| 5 |
Recruiting
|
A Study of Three Fixed-doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
| Conditions: |
Agitation Associated With; Alzheimer's Disease; Alzheimer's Type; Mental Disorder; Nervous System Diseases |
| Intervention: |
Drug: Brexpiprazole, OPC-34712 |
| Outcome Measures: |
The primary outcome is the change in the Cohen-Mansfield Agitation Inventory (CMAI) total score; The secondary outcome is the change in the Clinical Global Impression-Severity of Illness (CGI-S) score, as related to symptoms of Agitation |
|
| 6 |
Unknown †
|
Pre-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient
| Condition: |
Agitation |
| Interventions: |
Drug: Haloperidol; Drug: Midazolam |
| Outcome Measure: |
Time to sedation |
|
| 7 |
Recruiting
|
Dexmedetomidine to Prevent Agitation After Free Flap Surgery
| Conditions: |
Agitation; Delirium |
| Interventions: |
Drug: Dexmedetomidine; Drug: Saline placebo |
| Outcome Measures: |
Agitation in PACU; postoperative delirium |
|
| 8 |
Unknown †
|
Treatment Routes for Exploring Agitation
| Conditions: |
Dementia; Behavior Problems |
| Interventions: |
Behavioral: TREA (Treatment Routes for Exploring Agitation); Behavioral: Placebo Control Group |
| Outcome Measures: |
Agitation Behavior Mapping Instrument (ABMI); affect/mood measured by Lawton's behavior stream assessment |
|
| 9 |
Not yet recruiting
|
Vasculaire Leg Compression Device for the Treatment of Restless Legs Syndrome - A Prospective Clinical Study
| Conditions: |
Restless Legs Syndrome,; Restless Legs,; Ekbom Syndrome |
| Intervention: |
Device: Venous Health Systems Vasculaire Leg Compression Device |
| Outcome Measures: |
The Restless Legs Syndrome Rating Scale; The Restless Legs Syndrome-Quality of Life Instrument (RLS-QLI); The Epworth Sleepiness Scale (ESS); The Johns Hopkins Restless Legs Severity Scale (JHRLS); The International Restless Legs Syndrome Rating Scale |
|
| 10 |
Recruiting
|
Can Acetaminophen Given 1-2 Hours to Children Before Ear Tube Surgery Reduce Agitation After Anesthesia?
| Conditions: |
Emergence Agitation; Pain |
| Intervention: |
Drug: Acetaminophen |
| Outcome Measures: |
Emergence Agitation; Pain |
|
| 11 |
Unknown †
|
The Effect of Intramuscular Dexmedetomidine on Emergence Agitation in Children Undergoing With or Without Tube Insertion Under General Anesthesia
| Condition: |
Myringotomy |
| Intervention: |
Drug: Dexmedetomidine |
| Outcome Measures: |
Participant's Severity of Emergent Agitation (EA) using the Pediatric Anesthesia Emergence Delirium (PAED) scale in PACU (Post-Op Area).; Participant's Severity of Emergent Agitation (EA) in PACU (Post-Op Area) through Day 3 Post-Op using the Postanesthesia Discharge Scoring System (PADSS) score.; Participant's Severity of Emergent Agitation (EA) in PACU (Post-Op Area) through Day 3 Post-Op using the PADSS score. |
|
| 12 |
Recruiting
|
Reducing Agitation in People With Dementia: the Customized Activity Trial
| Condition: |
Dementia |
| Interventions: |
Behavioral: Tailored Activity Program; Other: Home Safety and Education Program |
| Outcome Measures: |
Frequency of Agitated Behavior in person with dementia; Frequency of agitated behaviors and quality of life in person with dementia; Caregiver wellbeing and time spent providing care; Cost effectiveness |
|
| 13 |
Unknown †
|
IM Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia
| Conditions: |
Schizophrenia; Schizoaffective Disorder; Agitation |
| Interventions: |
Drug: IM olanzapine; Drug: haloperidol plus lorazepam IM |
| Outcome Measures: |
Positive and Negative Symptom Scale Excited Component (PANSS-EC); Agitation-Calmness Evaluation Scale (ACES) |
|
| 14 |
Not yet recruiting
|
Treatment of Psychosis and Agitation in Alzheimer's Disease
| Conditions: |
Alzheimer's Disease; Psychosis; Agitation |
| Interventions: |
Drug: Lithium; Drug: Placebo |
| Outcome Measures: |
Change in Neuropsychiatric Inventory (NPI) Score; Clinical Global Impression (CGI) Global; Clinical Global Impression (CGI) Behavior; Young Mania Rating Scale; Treatment Emergent Signs and Symptoms (TESS); Simpson-Angus Scale; Basic Activities of Daily Living (BADL); Zarit Caregiver Burden Interview; Clinical Dementia Rating Scale (CDR) |
|
| 15 |
Unknown †
|
ED50 of Dexmedetomidine to Prevent Emergence Agitation in Children
| Condition: |
Agitation |
| Intervention: |
Drug: Dexmedetomidine |
| Outcome Measures: |
Agitation; pain |
|
| 16 |
Unknown †
|
The Effect of Dexmedetomidine on Emergence Agitation in Children Undergoing a Surgery Under Desflurane Anesthesia
| Condition: |
Psychomotor Agitation |
| Interventions: |
Drug: Dexmedetomidine; Drug: 0.9% Normal Saline |
| Outcome Measures: |
Agitation score; Oculomotor reflex |
|
| 17 |
Recruiting
|
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
| Condition: |
Alzheimer's Disease |
| Interventions: |
Drug: ELND005; Drug: Placebo |
| Outcome Measures: |
Change from Baseline in NPI-C combined Agitation and aggression subscores; Change from Baseline in modified-ADCS-CGIC Agitation scores; Change from Baseline in NPI total scores; Change from Baseline in MMSE scores; Change from Baseline in ADCS-ADL scores; Incidence and severity of adverse events |
|
| 18 |
Not yet recruiting
|
A RCT of Compound Lidocaine Cream to Prevent Postoperative Agitation in Patients With Endotracheal Intubation for GA
| Condition: |
Postoperative Agitation of Patients |
| Intervention: |
Drug: Compound Lidocaine Cream |
| Outcome Measures: |
Vital signs like blood pressure and heart rates during extubation.; The cough reflex and breath holding during extubation. |
|
| 19 |
Unknown †
|
Multidisciplinary Intervention for Challenging Behaviour (Agitation) in Patients With Dementia
| Condition: |
Dementia |
| Intervention: |
Behavioral: Psychosocial intervention |
| Outcome Measures: |
Agitation measured by the C-MAI (The Cohen-Mansfield Agitation Inventory); The Cornell scale for depression in dementia (CSDD); Neuropsychiatric Inventory (NPI ) which measures neuropsychiatric symptoms and behaviour; Lawton's self-maintenance scale (Lawton and Brody 1969), which measures function in activities of daily living (ADL); Quality of life in Alzheimers's Disease (QUALID) (Weiner et al. 2000), which measures quality of life; Staff measures: Psychosocial factors in work life will be measured by a scale developed by Sund (1992).; Use of antipsychotic drugs; Staff measures:P-cat:Person-centered Care Assessment Tool |
|
| 20 |
Unknown †
|
Dexmedetomidine to Lessen Intensive Care Unit (ICU) Agitation
| Condition: |
Delirium |
| Interventions: |
Drug: Dexmedetomidine; Drug: Saline placebo |
| Outcome Measures: |
Ventilator-free hours; Time to ICU discharge; Overall ICU length of stay; Time to first extubation; Time taken to achieve a satisfactory sedation score; %ICU time spent with a satisfactory sedation score; %ICU time spent with a satisfactory delirium score; Time taken to achieve a satisfactory Agitation score; %ICU time spent with a satisfactory Agitation score; Need for supplementary sedative medication; Need for mechanical restraint; Need for supplementary antipsychotic medication; Need for tracheostomy; Acute hospital length of stay; Discharge destination; Daily SOFA score; ICU mortality; Hospital mortality; Duration and rate of vasopressor support; Need for insertion of a new central venous catheter to facilitate vasopressor / inotropic support; Requirement for reintubation |
|
